{"disease":{"id":"complicated-urinary-tract-infection","name":"complicated urinary tract infection"},"drugs":{"marketed":[{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"relebactam","indication_name":"Complicated Urinary Tract Infections (cUTI), including Pyelonephritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"chembl-chembl3989564","indication_name":"Complicated and Recurrent Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fusidic-acid","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"gentamicin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"doripenem","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doribax","generic_name":"DORIPENEM","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"gepotidacin","indication_name":"Uncomplicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blujepa","generic_name":"GEPOTIDACIN","company_name":"Glaxosmithkline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":56,"revenue":null,"mechanism":"Blujepa works by inhibiting bacterial DNA polymerase, preventing the replication of bacterial DNA and ultimately leading to bacterial cell death."},{"drug_id":"tobramycin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"cefepime","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"CEFEPIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":59,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"cefpodoxime","indication_name":"Uncomplicated urinary tract infections (cystitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefepime-hydrochloride","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"Cefepime Hydrochloride","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":64,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"cefepim","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefepim","company_name":"University Hospital Tuebingen","drug_phase":"discontinued","molecular_target":"Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Uncomplicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"amikacin","indication_name":"Complicated Urinary Tract Infection due to Acinetobacter","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"amikacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"relebactam","indication_name":"Complicated Genitourinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"eravacycline","indication_name":"complicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"ticarcillin","indication_name":"Complicated Genitourinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Complicated Genitourinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Complicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Uncomplicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"levofloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"chembl-chembl1200962","indication_name":"Uncomplicated and Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"ofloxacine","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":36,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05385536","title":"Evaluating UTI Outcomes in at Risk Populations","phase":"","overall_status":"COMPLETED","enrollment_count":7921,"lead_sponsor_name":"Pathnostics","has_results":false},{"nct_id":"NCT03354598","title":"Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1671,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":true},{"nct_id":"NCT03357614","title":"Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1395,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":true},{"nct_id":"NCT03788967","title":"Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1372,"lead_sponsor_name":"Spero Therapeutics","has_results":true},{"nct_id":"NCT03638830","title":"Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":777,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT06996301","title":"Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.","phase":"NA","overall_status":"COMPLETED","enrollment_count":773,"lead_sponsor_name":"Doc Lab Inc","has_results":true},{"nct_id":"NCT05887908","title":"Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":614,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":true},{"nct_id":"NCT02486627","title":"A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":609,"lead_sponsor_name":"Achaogen, Inc.","has_results":true},{"nct_id":"NCT05733104","title":"A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT01345929","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":558,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04979806","title":"Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Wockhardt","has_results":false},{"nct_id":"NCT04876131","title":"Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":452,"lead_sponsor_name":"Murdoch Childrens Research Institute","has_results":false},{"nct_id":"NCT04076436","title":"Efficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions.","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT06885658","title":"Effectiveness of Visual Storytelling Intervention on Antibiotic Adherence in UTI Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":358,"lead_sponsor_name":"Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT05545137","title":"Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":299,"lead_sponsor_name":"Benova (Tianjin) Innovative medicine Research Co., Ltd.","has_results":false},{"nct_id":"NCT03425396","title":"Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Paratek Pharmaceuticals Inc","has_results":true},{"nct_id":"NCT02714595","title":"Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT05060419","title":"Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Qilu Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01096849","title":"A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Achaogen, Inc.","has_results":true},{"nct_id":"NCT05138822","title":"Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03230838","title":"MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT00921024","title":"Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT05905055","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT02728089","title":"Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04505683","title":"A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"Sihuan Pharmaceutical Holdings Group Ltd.","has_results":false},{"nct_id":"NCT02497781","title":"Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04215991","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT03293485","title":"Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03445195","title":"Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Entasis Therapeutics","has_results":true},{"nct_id":"NCT01970371","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Achaogen, Inc.","has_results":true},{"nct_id":"NCT03716804","title":"Establish the Relationship Between Shift in Prescribing Pattern and Associated Shift in Sensitivity Pattern of Causative Microbes in UTI Patients in a Closed Community","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","has_results":false},{"nct_id":"NCT04335539","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT05826990","title":"A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Allecra","has_results":false},{"nct_id":"NCT04476407","title":"Pharmacokinetics of Benapenem in Subjects With Renal Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Sihuan Pharmaceutical Holdings Group Ltd.","has_results":false},{"nct_id":"NCT03377426","title":"LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04682834","title":"Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Iterum Therapeutics, International Limited","has_results":false}],"total":36},"guidelines":[],"source":"Drug Landscape verified database"}